• KOL
    • Irritable Bowel Syndrome
    • Camilleri Camilleri
    • Camilleri Camilleri: Influence Statistics

      Camilleri Camilleri

      Camilleri Camilleri

      Show email address

      Clinical Enteric Neuroscience Translational and Epidemiological Research, Division of Gastroenterology and Hepatology, Mayo Clinic, Charlton Bldg., Rm. 8-110, 200 First Street ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Camilleri Camilleri:Expert Impact

      Concepts for whichCamilleri Camillerihas direct influence:Irritable bowel syndrome,Colonic transit,Gastric emptying,Bowel syndrome,Chronic constipation,Irritable bowel,Functional dyspepsia,Gastric volume.

      Camilleri Camilleri:KOL impact

      Concepts related to the work of other authors for whichfor which Camilleri Camilleri has influence:Irritable bowel syndrome,Functional dyspepsia,Gastric emptying,Chronic constipation,Abdominal pain,Gut microbiota,Gastrointestinal tract.

      KOL Resume for Camilleri Camilleri

      Year
      2022

      Clinical Enteric Neuroscience Translational and Epidemiological Research, Division of Gastroenterology and Hepatology, Mayo Clinic, Charlton Bldg., Rm. 8-110, 200 First Street S.W., Rochester, MN 55905, USA

      Precision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester MN, United States

      2021

      Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, MN, USA

      Mayo Clinic, Rochester, Minnesota.

      2020

      Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), and Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA

      Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN

      2019

      Division of Gastroenterology and Hepatology, Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, Minnesota

      Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, MN, US

      Mayo Clinic, Rochester, MN, United States of America.

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Camilleri Camilleri is among the top experts in the world.
      Concept World rank
      measure fasting #1
      eosinophilia dis #1
      rats gamma camera #1
      oic naldemedine #1
      mesenteric flow patients #1
      body weight esg #1
      gastric accommodation humans #1
      solids scintigraphy #1
      rates approximating egp #1
      placebo codeine #1
      renaissance understanding #1
      professional organizations approaches #1
      prucalopride oral solution #1
      colonic transit function #1
      dissecting molecular mechanisms #1
      ibsc bile acids #1
      ykp10811 #1
      effects dietary components #1
      studies optimal gastric #1
      pharmacological therapies ibsd #1
      slower colonic transit #1
      postprandial symptoms #1
      contractions relamorelin #1
      mechanical obstruction patients #1
      cholesterol absorption obesity #1
      bas feces #1
      acute administration codeine #1
      ibs diarrhea #1
      colonic transit colon #1
      tone ondansetron #1
      pyy obesity #1
      abdominal pain efficacy #1
      pharmacogenetics fgids #1
      gut dysmotility patients #1
      refractory constipation #1
      20 a3309 #1
      colonic sensory #1
      elobixibat effects #1
      satiation gastric #1
      imaging satiation #1
      antral axial forces #1
      diabetic gastroparesis placebo #1
      ileal mucosal biopsies #1
      infectious enteritis ibs #1
      postprandial colonic tone #1
      global endpoints fda #1
      ibs disorders #1
      positive agreement rom #1
      mtv symptoms #1
      gastric solids #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Camilleri Camilleri

      KOL-Index: 18821

      BACKGROUND: Liraglutide, a long-acting GLP-1 receptor agonist, is approved for treatment of obesity; however, the mechanisms of action of liraglutide are incompletely understood. We compared effects of liraglutide versus placebo on gastric motor functions, satiation, satiety, and weight in obese individuals over 16 weeks.

      METHODS: We did a randomised, double-blind, placebo-controlled pilot trial at a single centre (Mayo Clinic, Rochester, MN, USA). Participants were randomly allocated ...

      Known for Liraglutide Placebo | 16 Weeks | Weight Loss | Gastric Functions | Pilot Trial
      KOL-Index: 18024

      BACKGROUND: A subset of patients with constipation has reduced colonic bile acid concentrations, which are associated with slow colonic transit. In a previous study, elobixibat, a locally acting ileal bile acid transporter inhibitor, accelerated colonic transit in Japanese patients with functional constipation. In this study, we aimed to determine the efficacy of elobixibat for short-term treatment of chronic constipation, and safety, patient satisfaction, and quality of life with ...

      Known for Chronic Constipation | Patients Elobixibat | 3 Trial | Bile Acids | Week 2
      KOL-Index: 17119

      BACKGROUND: In this 12-week trial, we aimed to determine the efficacy of prucalopride, a selective, high-affinity 5-hydroxytryptamine4 receptor agonist, in patients with severe chronic constipation.

      METHODS: In our multicenter, randomized, placebo-controlled, parallel-group, phase 3 trial, patients with severe chronic constipation (< or =2 spontaneous, complete bowel movements per week) received placebo or 2 or 4 mg of prucalopride, once daily, for 12 weeks. The primary efficacy end ...

      Known for Severe Chronic Constipation | Prucalopride Patients | Placebo Week | Bowel Function | Controlled Trial
      KOL-Index: 16063

      IMPORTANCE: Five medications have been approved for the management of obesity, but data on comparative effectiveness are limited.

      OBJECTIVE: To compare weight loss and adverse events among drug treatments for obesity using a systematic review and network meta-analysis.

      DATA SOURCES: MEDLINE, EMBASE, Web of Science, Scopus, and Cochrane Central from inception to March 23, 2016; clinical trial registries.

      STUDY SELECTION: Randomized clinical trials conducted among overweight and obese ...

      Known for Weight Loss | 95 Cri | Pharmacological Treatments | Liraglutide Placebo | Orlistat Lorcaserin
      KOL-Index: 15290

      BACKGROUND & AIMS: There is an unclear relationship among bowel symptoms, excretion of unconjugated fecal bile acid (UBA), and colonic transit in irritable bowel syndrome (IBS). We measured total and main individual UBA in fecal samples of patients with IBS and assessed relationships among stool frequency or consistency, fecal UBA (total and individual), and colonic transit.

      METHODS: In this study 30 healthy volunteers (controls), 31 subjects with IBS with diarrhea (IBS-D), and 30 with ...

      Known for Colonic Transit | Bowel Functions | Bile Acid | Patients Ibs | Total Fecal
      KOL-Index: 14161

      BACKGROUND: Although novel therapies for irritable bowel syndrome (IBS) continue to be developed, many doctors rely on more established, traditional therapies as first-line or second-line treatment options. These therapies include soluble fibre (eg, ispaghula husk), antispasmodic drugs, peppermint oil, and gut-brain neuromodulators (including tricyclic antidepressants, selective serotonin reuptake inhibitors, or α-2-δ calcium channel subunit ligands). However, the relative efficacy of ...

      Known for Network Meta | Peppermint Oil | Bowel Syndrome | Abdominal Pain | Rcts Efficacy
      KOL-Index: 13837

      BACKGROUND & AIMS: Management of eosinophilic esophagitis (EoE) requires repeated endoscopic collection of mucosal samples to assess disease activity and response to therapy. An easier and less expensive means of monitoring of EoE is required. We compared the accuracy, safety, and tolerability of sample collection via Cytosponge (an ingestible gelatin capsule comprising compressed mesh attached to a string) with those of endoscopy for assessment of EoE.

      METHODS: Esophageal tissues were ...

      Known for Eosinophilic Esophagitis | Active Eoe | Cytosponge Endoscopy | Accuracy Safety | Eosinophils Field
      KOL-Index: 13534

      BACKGROUND: Microscopic colitis is diagnosed on the basis of histologic criteria, and irritable bowel syndrome (IBS) is diagnosed by symptom-based criteria. There has been little investigation into the symptomatic overlap between these conditions. Our aim was to assess the prevalence of symptoms of irritable bowel syndrome in a population-based cohort of patients with microscopic colitis.

      METHODS: The Rochester Epidemiology Project (REP), a medical records linkage system providing all ...

      Known for Microscopic Colitis | Irritable Bowel Syndrome | Symptomatic Overlap | Rome Criteria | Populationbased Cohort
      KOL-Index: 13504

      BACKGROUND & AIMS: Gastroparesis is a complication of diabetes with few treatment options. Relamorelin (also referred to as RM-131) is a selective, prokinetic agonist of ghrelin. We aimed to evaluate the efficacy of relamorelin on symptoms and gastric emptying (GE) in a 12-week, phase 2B study of diabetic patients with moderate to severe gastroparesis symptoms (DG).

      METHODS: We performed a study of 393 patients with DG (37.7% male; 9.9% with type 1 diabetes; median age, 58.2 years [range ...

      Known for Symptoms Gastroparesis | Vomiting Frequency | Efficacy Safety | Gastrointestinal Agents | Patients Dg
      KOL-Index: 13491

      BACKGROUND: About one-third of patients with IBS-diarrhoea (irritable bowel syndrome-D) have evidence of increased bile acid synthesis or excretion.

      AIMS: To assess effects of the bile acid sequestrant, colesevelam, on faecal excretion of BAs, hepatic BA synthesis and diarrhoea in IBS-D; to appraise whether individual or random stool samples accurately reflect 48-h total faecal bile acid excretion and proportions of the main bile acids excreted and to study the faecal fat excretion in ...

      Known for Bile Acids | Bowel Syndrome | Serum C4 | Effects Colesevelam | Hepatic Synthesis
      KOL-Index: 13435

      background & aims: Opiate bowel dysfunction is a significant clinical problem. Our aim was to evaluate the ability of a peripheral mu-opioid antagonist, alvimopan, to reverse the effect of codeine on gastric, small-bowel, and colonic transit time in healthy volunteers.

      METHODS: Seventy-four healthy participants (43 women) were randomized in a double-blind, placebo-controlled manner to 1 of 4 groups: alvimopan 12 mg twice daily in the presence and absence of codeine sulfate 30 mg 4 ...

      Known for Colonic Transit | Small Bowel | Alvimopan Placebo | 24 Hours | Codeine Gastrointestinal
      KOL-Index: 13373

      Our aim was to test the hypothesis that there is a relation between antral phasic pressure activity and the emptying of solids and liquids from the intact human stomach after a mixed meal. This hypothesis was evaluated in 14 healthy individuals in whom we performed simultaneous antral manometry and radioscintigraphy after ingestion of a meal labeled with [99mTc]sulfur colloid in cooked egg (solid component) and [111In]DTPA (liquid component). Analysis of the data included an in-depth ...

      Known for Antral Motility | Solids Liquids | Gastric Emptying | Liquid Phase | Mixed Meal
      KOL-Index: 12855

      BACKGROUND & AIMS: Peptide YY (PYY) levels are reported to be decreased in obesity. The relation between gastric functions, satiation, and gut hormones in obesity is incompletely understood. The aim of this study was to compare gastric volumes, emptying, maximum tolerated volumes, postchallenge symptoms, and selected gut hormones in normal, overweight, or obese healthy volunteers.

      METHODS: In 73 nonbulimic normal, overweight, or obese participants weighing less than 137 kg, we measured ...

      Known for Normal Weight | Pyy Levels | Gastric Volumes | Gastrointestinal Hormones | Satiation Volume
      KOL-Index: 12491

      OBJECTIVE: Over half of patients with IBS have either diarrhoea (IBS-D) or a mixed stool pattern (IBS-M). The relative efficacy of licenced pharmacological therapies is unclear in the absence of head-to-head trials. We conducted a network meta-analysis to resolve this uncertainty.

      DESIGN: We searched MEDLINE, Embase, Embase Classic, the Cochrane central register of controlled trials, and Clinicaltrials.gov through January 2019 to identify randomised controlled trials (RCTs) assessing the ...

      Known for Pharmacological Therapies | Network Meta | Abdominal Pain | Patients Ibs | Stool Consistency
      KOL-Index: 12422

      BACKGROUND: Impaired gastric accommodation may lead to dyspeptic symptoms. A non-invasive method using single photon emission computed tomography (SPECT) has been developed to measure gastric volumes.

      AIMS AND METHODS: Our aims were: to assess the accuracy of SPECT with three dimensional image analysis to measure balloon volumes in vitro; to compare gastric barostat balloon volumes measured post-meal and post-distension with total gastric volumes measured simultaneously with SPECT; to ...

      Known for Gastric Volumes | Spect Imaging | Dyspeptic Symptoms | Healthy Adults | Barostat Balloon

      Key People For Irritable Bowel Syndrome

      Top KOLs in the world
      #1
      Douglas A Drossman
      irritable bowel syndrome abdominal pain psychosocial factors
      #2
      Nicholas Joseph Talley
      functional dyspepsia irritable bowel syndrome emergency action
      #3
      William E Whitehead
      irritable bowel syndrome fecal incontinence abdominal pain
      #4
      Emeran A Mayer
      irritable bowel syndrome ibs patients food addiction
      #5
      Peter James Whorwell
      irritable bowel syndrome rectal sensitivity ulcerative colitis
      #6
      Robin Charles Spiller
      irritable bowel syndrome diverticular disease magnetic resonance

      Clinical Enteric Neuroscience Translational and Epidemiological Research, Division of Gastroenterology and Hepatology, Mayo Clinic, Charlton Bldg., Rm. 8-110, 200 First Street S.W., Rochester, MN 55905, USA | Division of Gastroenterology and Hepatolo

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.